Heise E, Parrish E, Cooper R
Tissue Antigens. 1979 Aug;14(2):98-104. doi: 10.1111/j.1399-0039.1979.tb00828.x.
Seventy-nine Caucasians with acute myelogenous leukemia (AML) were genotyped to determine whether AML, the induction of remission or patient survival were associated with particular HLA phenotypes or haplotypes. HLA-B17 and B27 were increased in AML patients over 40 years of age. Combined analysis of four independent studies indicates that HLA-B17 is significantly but weakly associated with AML, relative risk = 1.48 (.01 less than P less than .025). The A1, B17 and Aw24, Bw35 haplotypes occurred more frequently in the AML group as compared to racial and geographic controls (uncorrected P = 0.0068 and 0.0098, respectively Fisher's Exact Test). Induction of remission occurred less frequently in patients with the B17 phenotype as compared to patients lacking this antigen (P = 0.047). Patient survival was associated with remission status (P = 0.002) but was not significantly associated with particular HLA phenotypes or haplotypes. These results indicate that a gene or genes in the HLA-B region of the major histocompatibility complex can influence susceptibility to AML and also the response to chemotherapy.
对79名患有急性髓性白血病（AML）的高加索人进行基因分型，以确定AML、缓解诱导或患者生存率是否与特定的HLA表型或单倍型相关。40岁以上的AML患者中HLA - B17和B27有所增加。四项独立研究的综合分析表明，HLA - B17与AML存在显著但较弱的关联，相对风险 = 1.48（0.01 < P < 0.025）。与种族和地理对照相比，A1、B17以及Aw24、Bw35单倍型在AML组中出现的频率更高（分别采用Fisher精确检验，未校正的P值 = 0.0068和0.0098）。与缺乏该抗原的患者相比，具有B17表型的患者缓解诱导发生率较低（P = 0.047）。患者生存率与缓解状态相关（P = 0.002），但与特定的HLA表型或单倍型无显著关联。这些结果表明，主要组织相容性复合体HLA - B区域中的一个或多个基因可影响对AML的易感性以及对化疗的反应。
